X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Data from three randomized, placebo-controlled trials of nabiximols (GWMS0106, GWSP0604, and SAVANT) conducted were analyzed to assess the relationship between measures of spasticity and muscle strength in lower extremities or walking speed.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: Nabiximols
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
Results from post-hoc analysis of phase 3 clinical study show nabiximols was well-tolerated and provided continued reductions in spasticity for individuals who remained on therapy.
Lead Product(s): Tetrahydrocannabinol,Cannabidiol
Therapeutic Area: Neurology Product Name: Nabiximols
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 10, 2020
Details:
Epidiolex (cannabidiol), is a prescription, plant-derived cannabis-based medicine which is act CB receptor agonist, administered as an oral solution which contains highly purified cannabidiol (CBD), which is used for Lennox-Gastaut Syndrome and Dravet syndrome.
Lead Product(s): Cannabidiol
Therapeutic Area: Rare Diseases and Disorders Product Name: Epidiolex
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
